The disclosure is directed to novel predictive methods and personalized therapies for treating rheumatoid arthritis (RA). Specifically, the disclosure relates to predicting the likelihood of that a patient having RA will clinically respond to treatment with an an IL-17 binding molecule, e.g., an IL-17 antibody, such secukinumab.本發明係關於新穎的預測方法及治療類風濕性關節炎(RA)之個人化療法。特定而言,本發明係關於預測患有RA之患者將對以IL-17結合分子(例如IL-17抗體,諸如塞庫金單抗(secukinumab))治療有臨床反應之可能性。